-
Product Insights
NewFrontotemporal Dementia (FTD) – Drugs In Development, 2024
Empower your strategies with our Frontotemporal Dementia (FTD) – Drugs In Development, 2024 report and make more profitable business decisions. Frontotemporal dementia (FTD) encompasses various brain disorders leading to progressive damage in the frontal and temporal lobes. It manifests in distinct ways: behavioral changes, language difficulties, or movement impairments. Symptoms range from altered social conduct, lack of empathy, and impulsivity to language struggles or motor coordination issues. FTD's exact cause remains unclear, but abnormal protein deposits in the brain are implicated....
-
Product Insights
NewHuntington Disease – Drugs In Development, 2024
Empower your strategies with our Huntington Disease – Drugs In Development, 2024 report and make more profitable business decisions. Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow. The Huntington...
-
Product Insights
Huntington Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. This is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow. The Huntington Disease pipeline market research report provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Protein for Osteoarthritis and Asthma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Protein for Osteoarthritis and Asthma Drug Details Protein (allogenic mesenchymal trophic factors) is under...
-
Product Insights
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) – Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) pipeline Target constitutes close to 15 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The latest report Glial Cell Line Derived Neurotrophic Factor – Drugs In Development, 2022, outlays comprehensive information on the Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route...
-
Product Insights
Dementia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes, and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation, and cardiovascular diseases. The Dementia Drugs in Development market research report provides an overview of the Dementia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dementia,...
-
Product Insights
Alzheimer’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alzheimer’s Disease Drugs Development Report Overview Alzheimer's disease is a progressive, degenerative condition causing damage to memory and behavior due to the attack on the neurons. Predisposing factors include age, heredity, cardiovascular diseases or diabetes, and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability, and aggressiveness. Buy the Full Report for More Insights on the Alzheimer’s Disease Drugs in Development Report, Download a Free Sample The Alzheimer’s Disease Drugs in Development market research report provides an overview of the...
-
Sector Analysis
Stem Cells in Neurology
Stem cells in neurology is an evolving field. The current pipeline of products feature different types of stem cells and these therapies have the potential to target a range of neurological diseases. However, there are challenges associated with the development of these therapies, including the need to demonstrate strong safety and efficacy data. Biotechnology companies currently dominate in this field and are expected to lead the development of different pipeline products. The current pipeline consists of 16 products (Phase 1,2,...